Format

Send to

Choose Destination
Eur J Cancer Care (Engl). 2019 Jun 21:e13125. doi: 10.1111/ecc.13125. [Epub ahead of print]

Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.

Author information

1
Cancer Institute NSW, Alexandria, New South Wales, Australia.
2
University of Sydney and Mater Hospital, Sydney, New South Wales, Australia.
3
Liverpool Hospital, Liverpool, New South Wales, Australia.
4
Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia.
5
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

Abstract

OBJECTIVE:

To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer.

METHODS:

Linked data from New South Wales population-based and clinical cancer registries (2008-2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan-Meier and Cox proportional hazards methods.

RESULTS:

A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24-2.37 and OR 1.47, 95% CI 1.17-1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7-93.8) and were not hospitalised (93.1%, 95% CI 92.1-94.1).

CONCLUSION:

Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.

KEYWORDS:

adjuvant; antineoplastic agents; breast neoplasms; chemotherapy; drug-related side effects and adverse reactions; hospitalisation; survival

PMID:
31222826
DOI:
10.1111/ecc.13125

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center